Diffuse midline glioma (DMG) with H3K27M mutation is an aggressive and difficult to treat pediatric brain tumor. Recurrent gain of function mutations in H3.3 (H3.3A) and H3.1 (H3C2) at the 27th lysine to methionine (H3K27M) are seen in over 2/3 of DMGs, and are associated with a worse prognosis. Due to the anatomical location of DMG, traditional biopsy carries risk for neurologic injury as it requires penetration of vital midline structures. Further, radiographic (MRI) monitoring of DMG often shows non-specific changes, which makes therapeutic monitoring difficult. This indicates a critical need for more minimally invasive methods, such as liquid biopsy, to understand, diagnose, and monitor H3K27M DMG. He...
Midline astrocytic neoplasms have distinct molecular characteristics, quite different from astrocyti...
Diffuse intrinsic pontine glioma (DIPG) is a pediatric brainstem tumor with almost 100% rate of mort...
Background"Diffuse midline glioma (DMG), H3 K27M-mutant" is a new tumor entity established in the 20...
PurposePediatric diffuse midline glioma (DMG) are highly malignant tumors with poor clinical outcome...
Abstract Diffuse midline gliomas (including diffuse intrinsic pontine glioma, DIPG) are highly morbi...
Immunotherapy is currently being used to treat pediatric brain cancer, though its efficacy in treati...
Diffuse midline glioma (DMG) is a highly morbid pediatric brain tumor. Up to 80% of DMGs harbor muta...
Abstract Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (C...
BackgroundThe use of liquid biopsy is of potential high importance for children with high grade (HGG...
Background The use of liquid biopsy is of potential high importance for children with high grade (HG...
Glioblastomas are the most common malignant brain tumors in adults. Despite resection of the tumor, ...
Diffuse midline gliomas (DMGs) are pediatric high-grade brain tumors in the thalamus, midbrain, or p...
Abstract Diffuse midline glioma (DMG), H3 K27M-mutant, is a new entity in the updated WHO classifica...
BACKGROUND Children diagnosed with diffuse midline gliomas (DMG) have an extremely poor overall s...
Background: Diffuse Intrinsic Pontine Glioma (DIPG) is a deadly pediatric brain cancer that makes up...
Midline astrocytic neoplasms have distinct molecular characteristics, quite different from astrocyti...
Diffuse intrinsic pontine glioma (DIPG) is a pediatric brainstem tumor with almost 100% rate of mort...
Background"Diffuse midline glioma (DMG), H3 K27M-mutant" is a new tumor entity established in the 20...
PurposePediatric diffuse midline glioma (DMG) are highly malignant tumors with poor clinical outcome...
Abstract Diffuse midline gliomas (including diffuse intrinsic pontine glioma, DIPG) are highly morbi...
Immunotherapy is currently being used to treat pediatric brain cancer, though its efficacy in treati...
Diffuse midline glioma (DMG) is a highly morbid pediatric brain tumor. Up to 80% of DMGs harbor muta...
Abstract Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (C...
BackgroundThe use of liquid biopsy is of potential high importance for children with high grade (HGG...
Background The use of liquid biopsy is of potential high importance for children with high grade (HG...
Glioblastomas are the most common malignant brain tumors in adults. Despite resection of the tumor, ...
Diffuse midline gliomas (DMGs) are pediatric high-grade brain tumors in the thalamus, midbrain, or p...
Abstract Diffuse midline glioma (DMG), H3 K27M-mutant, is a new entity in the updated WHO classifica...
BACKGROUND Children diagnosed with diffuse midline gliomas (DMG) have an extremely poor overall s...
Background: Diffuse Intrinsic Pontine Glioma (DIPG) is a deadly pediatric brain cancer that makes up...
Midline astrocytic neoplasms have distinct molecular characteristics, quite different from astrocyti...
Diffuse intrinsic pontine glioma (DIPG) is a pediatric brainstem tumor with almost 100% rate of mort...
Background"Diffuse midline glioma (DMG), H3 K27M-mutant" is a new tumor entity established in the 20...